Skip to main content

yutrepia

Generic: treprostinil

yutrepia: developed by 1 company · 1 FDA decision.

yutrepia evidence translation

What we can confirm

What it means

Source-backed records connect yutrepia to LQDA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could yutrepia → LQDA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Liquidia Corp (LQDA)
Pulmonary arterial hypertension (PAH) and pulmonary hyperten…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately i(LQDA)FDA ↗
NDA213005Type 5 - New Formulation or New ManufacturerStandardInhalationPowder

Frequently asked questions

Who is developing yutrepia?

yutrepia is being developed by Liquidia Corp.

What is yutrepia's latest FDA decision?

The most recent tracked FDA decision for yutrepia is Approval for 1 INDICATIONS AND USAGE • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately i, dated May 23, 2025.